CHASE, THOMAS N.,雀斯汤玛斯Ｎ,雀斯湯瑪斯Ｎ,SASAKI, KEISHIN,佐佐木经世,佐佐木經世,KOGA, MINAKO,古贺三奈子,古賀三奈子,雀斯汤玛斯N,雀斯湯瑪斯N
申请号：
TW103103942
公开号：
TW201444973A
申请日:
2014.02.06
申请国别(地区):
TW
年份:
2014
代理人:
摘要：
Methods are described for the isolation and selection of a heterogeneous bone marrow cell population, called NCS-01, that is effective at treating neurodegeneration. For example, NCS-01 cells are shown to treat neurodegeneration caused by ischemia. In vivo studies demonstrate that selected NCS-01 cell populations treat neurodegeneration in a standard rat middle cerebral artery occlusion (MCAO) animal model under conditions of transient or permanent total arterial occlusion. These studies also disclose that when the neurodegeneration is caused by ischemic stroke, combining the administration of a selected NCS-01 cell population with thrombolytic agents and/or mechanical methods of clot removal leads to a decrease in the volume of infarction caused by acute onset neurodegeneration. The disclosed cell therapy promises to make a significant clinical impact on patient survival after stroke.所述方法是用於分離及篩選異質骨髓細胞族群，稱為NCS-01，NCS-01細胞有效用於治療神經退化。例如，顯示NCS-01細胞可治療缺血所造成的神經退化。體內研究證明所選出的NCS-01細胞族群能治療處於暫時性或永久性完全動脈阻塞情況下之標準大鼠中大腦動脈阻塞(MCAO)動物模型中的神經退化。這些研究亦揭示當缺血性中風造成神經退化時，合併施用所選出的NCS-01細胞族群與血栓溶解劑及/或機械式血塊移除方法能使因急性發作神經退化所造成的梗塞體積減少。所揭示的細胞治療方法有望對中風後存活患者造成顯著的臨床效果。
